MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma

A significant fraction of patients with lung adenocarcinomas harboring activating epidermal growth factor receptor (EGFR) mutations do not experience clinical benefits from EGFR tyrosine kinase inhibitor (TKI) therapy. Using next-generation sequencing, we screened 739 mutation hotspots in 46 cancer-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Chao-Hua, Ho, Hsiang-Ling, Doong, Howard, Yeh, Yi-Chen, Chen, Mei-Yu, Chou, Teh-Ying, Tsai, Chun-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480762/
https://www.ncbi.nlm.nih.gov/pubmed/25823662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480762/
https://www.ncbi.nlm.nih.gov/pubmed/25823662

Ejemplares similares